Scienture's Q3 Revenue Jumps on New Product Launch and Arbli Growth
Scienture Holdings reported preliminary unaudited third-quarter 2026 revenue of about $1.22 million, a 256% increase from the second quarter. The company attributed the growth to the August 2026 launch of REZENOPY and rising sales of Arbli. Arbli wholesale unit sales rose 74% sequentially.
Scienture Holdings, based in Commack, N.Y., released preliminary unaudited figures on Oct. 13, 2026. Third-quarter revenue ended Sept. 30 was about $1.22 million, compared with roughly $344,000 in the prior quarter. The company linked the gain to REZENOPY's August 2026 launch, first wholesale shipments, and Arbli's growing adoption. Arbli wholesale unit volume rose 74% from the second quarter, helped by new institutional formulary listings.
Arbli is a liquid losartan formulation approved for hypertension in patients older than six, stroke-risk reduction in certain hypertension patients with left ventricular hypertrophy, and diabetic nephropathy in some type 2 diabetes patients. Scienture says it avoids compounding, uses a smaller dose volume, and stores at room temperature. REZENOPY is its second FDA-approved commercial product. Final Q3 results will appear in a Form 10-Q.
Count words. First para: Scienture(1) Holdings2 based3 in4 Commack5 N.Y.6 released7 preliminary8 unaudited9 figures10 on11 Oct.12 13,13 2026.14 Third-quarter15 revenue16 ended17 Sept.18 30 19 was20 about21 $1.22 22 million,23 compared24 with25 roughly26 $344,00027 in28 the29 prior30 quarter.31 The32 company33 linked34 the35 gain36 to37 REZENOPY's38 August39 2026 40 launch,41 first42 wholesale43 shipments,44 and45 Arbli's46 growing47 adoption.48 Arbli49 wholesale50 unit51 volume52 rose53 74%54 from55 the56 second57 quarter,58 helped59 by60 new61 institutional62 formulary63 listings.64. Second: Arbli65 is66
The launch and sales growth could affect patients, caregivers, prescribers, and investors. A ready-to-use liquid losartan option may make hypertension treatment easier for some patients, especially those who struggle with tablets or compounding. Institutional formulary additions may influence prescribing and pharmacy access. For Scienture, rising revenue may support hiring, partnerships, and pipeline investment, though preliminary figures remain unaudited and commercial adoption could vary. Count: The1 launch2 and3 sales4 growth5 could6 affect7 patients,8 caregivers,9 prescribers,10 and11 investors.12 A13 ready-to-use14 liquid15 losartan16 option17 may18 make19 hypertension20 treatment21 easier22 for23 some24 patients,25 especially26 those27 who28 struggle29 with30 tablets31 or32 compounding.33 Institutional34 formulary35 additions36 may37 influence38 prescribing39 and40 pharmacy41 access.42 For43 Scienture,44 rising45 revenue46 may47 support48 hiring,49 partnerships,50 and51 pipeline